Solid Biosciences Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022. Solid Biosciences is a clinical-stage biotechnology company developing gene therapies for Duchenne muscular dystrophy (Duchenne). It reported no product sales; its revenue was collaboration revenue from Ultragenyx. Unless otherwise stated, financial amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Collaboration revenue | $1.9 million | $3.3 million |
| Research and development expense | $19.9 million | $14.2 million |
| General and administrative expense | $7.4 million | $6.0 million |
| Total operating expenses | $27.3 million | $20.2 million |
| Net loss | $25.3 million | $16.9 million |
| Basic and diluted net loss per share | $0.22 | $0.19 |
| Cash used in operating activities | $27.2 million | $21.4 million |
- Revenue fell 42%, primarily because of reduced research services and reimbursable costs under the Ultragenyx collaboration. R&D expense rose 40%, led by higher SGT-003 and other program costs and personnel expense; SGT-001 expense decreased.
- At March 31, 2022, cash and cash equivalents were $129.7 million and available-for-sale securities were $50.3 million, totaling $180.1 million. Total assets were $207.6 million and total liabilities were $22.0 million. The company reported no debt outstanding; liabilities included operating and finance lease obligations.
- Operating cash use increased year over year. Investing activities provided $37.7 million, mainly from security maturities and sales, while financing activities provided less than $0.1 million. The resulting $10.6 million increase in cash, cash equivalents and restricted cash reflects portfolio activity, not operating cash generation.
- Accumulated deficit was $502.1 million. There was no income tax benefit recorded, as the company maintained a full valuation allowance on deferred tax assets.
Programs, changes and outlook
- SGT-001: In March 2022, the company reported two-year interim safety and efficacy observations for the first three patients in the 2E14 vg/kg cohort of IGNITE DMD. Results were described as suggesting durable benefit across functional, pulmonary and patient-reported measures versus natural-history trajectories. The company reported no new drug-related safety findings in dosed patients during post-dosing periods ranging from 90 days to approximately four years. These are interim findings, and the filing cautions that preliminary data may change.
- Enrollment in IGNITE DMD was concluded in April 2022; patients are to be monitored for five years after treatment. The company said it expected to resume SGT-001 dosing in 2023, subject to FDA discussions, using a planned outsourced, transient-transfection manufacturing process.
- SGT-003: The company described preclinical findings for its next-generation capsid, including improved muscle tropism and reduced liver biodistribution versus AAV9 in a non-human-primate reporter study. It expected an IND submission in early 2023. Preclinical results do not establish clinical safety or efficacy.
- After quarter-end, the company announced a strategic shift to prioritize SGT-001, SGT-003 and next-generation capsids, streamline operations, and reduce headcount by approximately 35%. It estimated restructuring costs of $1.7 million, with payments expected across the remainder of 2022. The company projected that March 31 cash, cash equivalents and securities, together with lower planned spending, would fund operations into Q2 2024. This is a management estimate based on assumptions, not a guarantee.
- The financial-statement liquidity note said resources were expected to cover operating and capital needs for at least 12 months from issuance; the later Q2 2024 runway estimate incorporates the April restructuring. The company expects continuing losses and may need additional financing thereafter. No committed external funding source was identified.
Risks, contingencies and other notable items
- SGT-001 previously faced an FDA clinical hold following a serious adverse event; the hold was lifted in October 2020. The filing also discusses a drug-related serious adverse event in a patient treated in April 2021 and emphasizes the potential for further serious events, trial delays, or regulatory restrictions.
- The planned manufacturing-process change may require comparability work or additional preclinical or clinical studies. The company had not yet completed a clinical-supply manufacturing run using the transient-transfection process and noted risks of variability, inadequate yield, and supply delays.
- The company’s products remain investigational. Development, regulatory approval, manufacturing scale-up, competition, intellectual-property rights, collaboration performance, and access to future capital are significant risks. COVID-19-related disruption may also affect trials and operations.
- The Ultragenyx agreement provides cost reimbursement and potential future milestones and royalties, subject to its terms; the company recognized $1.9 million of related-party collaboration revenue in Q1. Deferred collaboration revenue was $6.2 million at March 31, 2022. Ultragenyx may terminate the agreement on 90 days’ notice.
- The company reported no material legal proceedings and no material change in internal control over financial reporting; management concluded disclosure controls were effective at a reasonable-assurance level.
Most important facts for investors to verify
- Whether the reported interim SGT-001 observations are sustained in longer follow-up and whether the full clinical data support the company’s interpretation.
- FDA feedback, the timing and conditions for future SGT-001 dosing, and progress toward the expected SGT-003 IND submission.
- Whether the new manufacturing process can reliably produce clinical material, what comparability evidence regulators require, and any resulting cost or timeline changes.
- Actual spending, restructuring costs and savings, and whether the stated runway into Q2 2024 remains achievable.
- Future funding needs and potential dilution, and developments in the Ultragenyx collaboration, including reimbursements, milestones, termination rights and deferred-revenue recognition.